DexCom (NASDAQ:DXCM) Given New $100.00 Price Target at JPMor

DexCom (NASDAQ:DXCM – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $160.00 to $100.00 in a report issued on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical device company’s stock. Several other equities research analysts have also issued reports on the company. […]

Related Keywords

United States , , Canaccord Genuity Group , Rock Asset Management , Dexcom Inc , Jpmorgan Chase Co , Resources Investment Advisors , Dexcom Company Profile , Securities Exchange Commission , Vontobel Holding Ltd , Barclays , Financial Counselors Inc , Citigroup , Free Report , Genuity Group , Moderate Buy , Com Stock Down , Get Free Report , Director Bridgette , Exchange Commission , Investment Advisors , Trail Advisors , Spouting Rock Asset Management , Dexcom Share , Dexcom Real Time , Dexcom Daily , Dexcom , Nasdaq Dxcm , Dxcm , Medical , 25213110 , Lower Price Target ,